Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2

Figure 4

Upregulation of NOD2 can overcome resistance to lenvatinib in HCC cells. (a) mRNA levels of NOD2 were measured in HepG2 and HepG2/R cells. (b) Protein levels of NOD2 were measured in HepG2 and HepG2/R cells. (c) HepG2/R cells were transfected with pcDNA or pcNOD2 for 24 h, and mRNA levels of NOD2 were measured. (d) Protein levels of NOD2 were measured. (e) HepG2/R cells were transfected with pcDNA or pcNOD2 for 24 h, then cells were treated with or without lenvatinib (10 μM) for another 24 h, and cellular death was measured. (f) Cells were treated as described above, and relative caspase-3/7 activities were measured. (g) HepG2/R cells were transfected with pcDNA or pcNOD2 for 24 h, then cells were treated with or without lenvatinib (10 μM) for another 24 h, and cellular viabilities were measured. The data was presented as . .

(a)

(b)

(c)

(d)

(e)

(f)

(g)